← All trials
NCT05343455
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 29, 2022
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Apr 25, 2022
- Last posted
- Aug 30, 2022
- Enrollment
- 320
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fortress BiotechLead sponsor
- Fortress BiotechStudy director
- Dr. Reddy's LaboratoriesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.